Grifols has declared a net profit of 88 million euros in the first nine months of the year, which represents an increase of 102 million euros compared to the same period of the previous year. “He net profit is affected by certain non-recurring financial and tax expenses associated with the company’s efforts to reduce its debt and the operation of Sraas. Excluding these elements, the net profit amounted to 264 million euros in the first nine months of the year,” says the multinational blood products company in a statement.
In the middle of the process to proceed with a delisting takeover bid by Brookfield, the multinational of blood products reports revenues of 5,237 million euros, 9.1% more, while the adjusted gross operating result (Ebitda) increased 25% year-on-year, to 1,253 million euros, driven by the strength of its Biopharma division.
Nacho Abia, CEO of Grifols, declared that he was “proud of the good results obtained in the third quarter». «Thanks to the entire Grifols team, we have managed to drive growth, maintain disciplined cost control and advance our continuous improvement initiatives. With this work underway and our solid fundamentals, we continue to make progress in achieving our objectives for 2024,” says the company’s head.
Grifols, in this context, insists that “deleveraging continues to be an absolute priority for Grifols.” “The leverage ratio “has stood at 5.1×4 in the third quarter, showing an improvement compared to the 5.5x of the second quarter and the 6.8x of the first quarter,” adds the firm, facing the end of a year marked by the attack in January of the bearish fund Gotham.
#Grifols #earns #million #September #compared #losses #year
